Background/Aims: To explore the presenting and early symptoms of dementia with Lewy bodies (DLB). Method: Patients with mild dementia fulfilling diagnostic criteria for DLB (n = 61) and Alzheimer’s disease (AD) (n = 109) were recruited from outpatient dementia clinics in western Norway. At diagnosis, caregivers were asked which symptom had been the presenting symptom of dementia. Results: Caregivers reported that memory impairment was the most common presenting symptom in DLB (57%), followed by visual hallucinations (44%), depression (34%), problem solving difficulties (33%), gait problems (28%), and tremor/stiffness (25%). In contrast, 99% of AD carers reported impaired memory as a presenting symptom, whereas visual hallucinations were a presenting symptom in 3% of the AD cases. Conclusion: DLB should be suspected in predementia cases with visual hallucinations.

Keywords:
Dementia with Lewy bodies, Alzheimer’s disease dementia, Parkinsonism, Predementia, Carer report
1.
McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–1872.
2.
Aarsland D, Rongve A, Nore SP, et al: Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008;26:445–452.
3.
Williams MM, Xiong C, Morris JC, Galvin JE: Survival and mortality differences between dementia with Lewy bodies vs. Alzheimer disease. Neurology 2006;67:1935–1941.
4.
Bostrom F, Jonsson L, Minthon L, Londos E: Patients with Lewy body dementia use more resources than those with Alzheimer’s disease. Int J Geriatr Psychiatry 2007;22:713–719.
5.
Bostrom F, Jonsson L, Minthon L, Londos E: Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:150–154.
6.
Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF: REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75:494–499.
7.
Iranzo A, Lomena F, Stockner H, et al: Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study (corrected). Lancet Neurol 2010;9:1070–1077 (erratum in Lancet Neurol 2010;9:1045).
8.
Molano J, Boeve B, Ferman T, et al: Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;133:2–56.
9.
Jicha GA, Schmitt FA, Abner E, et al: Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging 2010;31:1805–1813.
10.
Sonnesyn H, Nilsen DW, Rongve A, et al: High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord 2009;28:307–313.
11.
Kaufmann H, Nahm K, Purohit D, Wolfe D: Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004;63:1093–1095.
12.
Tolosa E, Borght TV, Moreno E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group: Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007;22:2346–2351.
13.
Hirano S, Asahina M, Uchida Y, et al: Reduced perfusion in the anterior cingulate cortex of patients with pure autonomic failure: an 123I-IMP SPECT study. J Neurol Neurosurg Psychiatry 2009;80:1053–1055.
14.
Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D: Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008;70:1017–1022.
15.
Lippa CF, Duda JE, Grossman M, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812–819.
16.
Dubois B, Feldman HH, Jacova C, et al: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
17.
Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA: One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753–761.
18.
McKeith I, O’Brien J, Walker Z, et al: Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–313.
19.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
20.
Dubois B, Burn D, Goetz C, et al: Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314–2324.
21.
Rongve A, Bronnick K, Ballard C, Aarsland D: Core and suggestive symptoms of dementia with Lewy bodies cluster in persons with mild dementia. Dement Geriatr Cogn Disord 2010;29:317–324.
22.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
23.
Walker MP, Ayre GA, Cummings JL, et al: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252–256.
24.
Ferman TJ, Smith GE, Boeve BF, et al: DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181–187.
25.
Boeve BF, Ferman TJ, Silber MH, Smith GE: Validation of a questionnaire of REM sleep behavior disorder. Neurology 2002;58(suppl 3):A509.
26.
Fahn S, Elton R, Members of the UPDRS development committee: Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson’s Disease. Florham Park, MacMillan Health Care Information, 1987, pp 153–163.
27.
Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J: What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain 2006;129:3–35.
28.
Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.
29.
Harding AJ, Broe GA, Halliday GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:2–403.
30.
Ballard C, Piggott M, Johnson M, et al: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868–876.
31.
Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
32.
Alafuzoff I, Ince PG, Arzberger T, et al: Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:635–652.
33.
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW: Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004;56:173–181.
34.
Friedman JH: Gait in the elderly. Med Health RI 2008;91:134–135.
35.
Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y: Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 2004;19:60–67.
36.
Caviness JN, Driver-Dunckley E, Connor DJ, et al: Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 2007;22:1272–1277.
37.
Naismith SL, Pereira M, Shine JM, Lewis SJ: How well do caregivers detect mild cognitive change in Parkinson’s disease? Mov Disord 2011;26:161–164.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.